Differentiating Factors Between Erythropoiesis-Stimulating AgentsA Guide to Selection for Anaemia of Chronic Kidney Disease

被引:0
|
作者
Robert Deicher
Walter H. Hörl
机构
[1] University of Vienna,Division of Nephrology and Dialysis, Department of Medicine III
[2] Universitätsklinik für Innere Medizin III,Klinische Abteilung für Nephrologie und Dialyse
来源
Drugs | 2004年 / 64卷
关键词
Chronic Kidney Disease; Subcutaneous Administration; Peritoneal Dialysis Patient; Sialic Acid Residue; Erythropoiesis Stimulate Agent;
D O I
暂无
中图分类号
学科分类号
摘要
Endogenous erythropoietin (EPO) consists of a central polypeptide core covered by post-translationally linked carbohydrates. Three of the four currently available erythropoiesis stimulating agents (ESA) — epoetin-α, epoetin-β and epoetin-ω — are composed of an identical amino acid sequence, but glycosylation varies as a result of type- and host cell-specific differences in the production process.
引用
收藏
页码:499 / 509
页数:10
相关论文
共 50 条
  • [1] Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease
    Walter H. Hörl
    Drugs, 2013, 73 : 117 - 130
  • [2] Equipotent Doses of Erythropoiesis-Stimulating Agents in Outpatients with Anaemia Secondary to Chronic Kidney Disease
    Escudero-Vilaplana, Vicente
    Martinez-Nieto, Concepcion
    Manuel Lopez-Gomez, Juan
    Vega-Martinez, Almudena
    Sanjurjo-Saez, Maria
    LATIN AMERICAN JOURNAL OF PHARMACY, 2013, 32 (03): : 454 - 458
  • [3] Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis
    Escudero-Vilaplana, Vicente
    Martinez-Nieto, Concepcion
    Manuel Lopez-Gomez, Juan
    Vega-Martinez, Almudena
    Maria Bellon-Cano, Jose
    Sanjurjo-Saez, Maria
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (03) : 463 - 468
  • [4] Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis
    Vicente Escudero-Vilaplana
    Concepción Martínez-Nieto
    Juan Manuel López-Gómez
    Almudena Vega-Martínez
    José María Bellón-Cano
    María Sanjurjo-Sáez
    International Journal of Clinical Pharmacy, 2013, 35 : 463 - 468
  • [5] Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease
    Carrero, Juan Jesus
    Barany, Peter
    Yilmaz, Mahmut Ilker
    Qureshi, Abdul Rashid
    Sonmez, Alper
    Heimburger, Olof
    Ozgurtas, Tanez
    Yenicesu, Mujdat
    Lindholm, Bengt
    Stenvinkel, Peter
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (02) : 709 - 715
  • [6] An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease
    Del Vecchio, Lucia
    Locatelli, Francesco
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (08) : 1021 - 1030
  • [7] Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients
    Amnuay, Kamalas
    Srisawat, Nattachai
    Wudhikarn, Kitsada
    Assanasen, Thamathorn
    Polprasert, Chantana
    HEMATOLOGY REPORTS, 2019, 11 (03) : 61 - 64
  • [8] Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer
    Hazzan, Azzour D.
    Shah, Hitesh H.
    Hong, Susana
    Sakhiya, Vipulbhai
    Wanchoo, Rimda
    Fishbane, Steven
    KIDNEY INTERNATIONAL, 2014, 86 (01) : 34 - 39
  • [9] Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
    Ngo, Katherine
    Kotecha, Dipak
    Walters, Julia A. E.
    Manzano, Luis
    Palazzuoli, Alberto
    van Veldhuisen, Dirk J.
    Flather, Marcus
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01):
  • [10] Modulation of Platelet Activation in Chronic Kidney Disease Patients on Erythropoiesis-Stimulating Agents
    Farag, Youssef M. K.
    Keithy-Reddy, Sai Ram
    Mittal, Bharati V.
    Bansal, Vinod
    Fareed, Jaweed
    Singh, Ajay K.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2012, 18 (05) : 453 - 461